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A B S T R A C T
Iron levels in the healthy human brain are known to be high in certain areas such as the substantia nigra (SN),
and increase further with age. In addition, there is some evidence for a further increase in iron load in the SN of
Parkinsońs disease (PD) patients as compared to controls, which correlates with motor disability. Here, we have
analyzed total iron levels in cells as well as mouse and human brain samples by atomic absorption spectroscopy
(AAS). Our data indicate that iron load is more pronounced in cells with dopaminergic features. Moreover,
region-specific differences in iron load reflecting those in the human brain were detected in rodent brains as
well. Whilst altered iron load was not observed in other regions also affected in PD patients, we report a
significant increase in iron load in the SN of Lewy body disease patients as compared to Alzheimeŕs disease (AD)
patients or controls, which correlates with neurodegeneration in this brain area.
1. Introduction
Iron is an important transition metal which plays a crucial role in
many chemical reactions such as oxidative phosphorylation, myelin
production or the synthesis and metabolism of neurotransmitters [1,2].
However, excess iron can cause hydroxyl radical production via the
Fenton reaction, leading to oxidative stress accompanied by the
oxidation and modification of proteins, lipids, carbohydrates and
DNA [3,2]. Therefore, cellular iron levels tend to be tightly regulated.
During healthy ageing, iron is known to accumulate in several brain
regions and cell types [2]. Generally the highest concentrations of iron
are found in the substantia nigra (SN) as well as in the dopaminergic
projection areas of the striatum including caudate nucleus and putamen
[3,4]. Interestingly, these are the sites most vulnerable to neurodegen-
eration underlying parkinsonian phenotypes, suggesting that excessive
iron accumulation in those areas may contribute to neurodegeneration
through generation of oxidative stress and resultant neuronal vulner-
ability [2,5].
Neuropathologically, Parkinsońs disease (PD) is characterized by
the relatively selective loss of dopaminergic neurons in the SN, with
Lewy bodies (LBs) rich in α-synuclein present in surviving neurons.
Additional brain areas, such as the caudate nucleus, are also known to
be particularly affected during relatively early stages of disease
development [6,7]. Other neurodegenerative disorders such as Lewy
Body Disease (LBD) are characterized by the presence of LBs in the SN,
but in contrast to PD present with widespread LB pathology [8,9].
Finally, Alzheimer disease (AD) pathology is characterized by senile
plaques rich in Aβ and abnormal tau depositions in distinct areas
throughout the brain [10]. The link between increased iron content and
region-specific neuropathological changes and cell death in the distinct
neurodegenerative diseases has remained largely unclear.
Given the particularly high levels of iron in the SN, many studies
have aimed to determine alterations in total iron content in areas
vulnerable to neurodegeneration in PD patients as compared to healthy
controls. Distinct in vivo magnetic resonance imaging (MRI) approaches
have reported increases in iron load in the SN of PD patients as
compared to healthy controls, but contradictory results have been
obtained in other brain areas such as the putamen or caudate nucleus
(reviewed in [11]. However, there are limitations with respect to iron
imaging using MRI approaches, as signals can be confounded by other
factors such as calcium, lipid or myelin content [12,13,11]. Therefore,
careful analysis of total iron content in postmortem samples is crucial
towards establishing a clear correlation between increased iron load and
neurodegeneration in PD. Analysis of iron content from postmortem
samples have yielded conflicting outcomes, with either no change or an
increase in total iron content in the SN and putamen of PD patients as
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compared to controls, and absolute values differing by a factor of almost
10 (reviewed in [14,11]. Amongst those studies, iron determinations
have been performed using distinct techniques such as X-ray fluorescent
spectroscopy, inductively coupled plasma spectroscopy, atomic absorp-
tion spectroscopy (AAS), spectrophotometry, colorimetry or Mossbauer
spectroscopy [15,16,14,17,18,19,20,21,22,23,11,24,25] reviewed in
[14,11]. At least in some cases, heterogeneity of the results may have
been due to the differential sensitivities and specificities of the methods
employed. However, other factors such as differences in age or disease
state of patients, or methods of sample collection, sample storage or
sample size may have contributed to the observed discrepant findings as
well.
The aim of the present study was to develop a sensitive and
reproducible method for detecting total iron levels in cellular, animal-
derived and human-derived brain samples using AAS, and to gauge for
region-specific differences in iron overload in various neurodegenera-
tive diseases.
2. Materials and methods
2.1. Cells and sample preparation
HEK293T and rat dopaminergic neuroendocrine PC12 cells were
cultured as described before [28]. Cells were treated with ferric
ammonium citrate (FAC; Sigma Aldrich, F5879) using the indicated
concentrations and times, and cell extracts prepared from a 100 mm
dish by scraping cells off the dish in the presence of 1 ml ice-cold
phosphate-buffered saline (PBS). Resuspended cells were centrifuged at
16,100g for 10 min at 4 °C, and wet weight of the cell pellet was
determined before sample digestion using 500 μl of pure HNO3 at 65 °C
during 2 h. The resulting lysates were subjected to AAS determination
without further dilution. Total iron content was normalized to either
wet weight or to total protein content as determined by Bradford assay
(Thermo Scientific, 23227) upon appropriate dilution of samples
[29,30].
2.2. Animals and sample preparation
Both inbred C57BL/6 and outbred CD-1 mice were obtained from
Charles River, and housed under standard conditions of light, tempera-
ture and humidity with unlimited access to water and food. All
experimental animal protocols and animal procedures complied with
National guidelines for the care and use of laboratory animals, and were
according to principles and directives of the European Communities
Council Directives. Animals were either two or nine months old at the
time of sample preparation. Animals were sacrificed by cervical
dislocation, and brain tissue was quickly dissected on ice. Cortex,
cerebellum and substantia nigra were obtained, wet weight determined,
cut into smaller pieces if necessary and samples immediately frozen and
stored under liquid nitrogen. Frozen samples from each region were
resuspended in 500 μl of pure HNO3 for 2 h at 65 °C. Four additional
protocols were employed, which included: 1) resuspension of samples
in 500 μl of a mix of pure NHO3 and H2O2 (1:1) and incubation at 90 °C
for 2 h; 2) resuspension of slices in 500 μl of pure HNO3 overnight at
room temperature, followed by heating samples for 20 min at 90 °C the
following day, addition of an equal volume of H2O2 and incubation for
15 min at 70 °C; 3) resuspension of samples in 500 μl cell lysis buffer
(1% SDS in PBS, pH 7.4 containing 1 mM PMSF, 1 mM Na3VO4 and
5 mM NaF) Dounce homogenized and sonicated; 4) resuspension of
samples in 250 μl cell lysis buffer, Dounce homogenization and sonica-
tion, followed by addition of 250 μl pure HNO3. In all cases, lysates
were mixed and sonicated twice during incubations, and centrifuged at
3500 × g for 30 min at 4 °C. An aliquot was taken for quantification of
iron content and the remainder was frozen down. Samples were
subjected to AAS upon a 1:10 dilution in MilliQ H2O. Total iron content
was normalized to either wet weight or to total protein content as
determined by Bradford assay (Thermo Scientific, 23227) upon appro-
priate dilution of samples [31].
2.3. Human postmortem tissue and sample preparation
Samples from three patients with PD and three age-matched
controls, or from five patients with LBD, five patients with AD and five
age-matched controls were obtained at postmortem following informed
consent from next of kin, and under a protocol approved by the Local
Ethics Committee of the Bellvitge University Hospital (June 2014,
reference number PR059/14). The postmortem delay between death
and tissue processing was betweeen 4 and 9 h, and the pH of the brain
was between 6.6 and 6.9 in all cases. One-half of the brain was
immediately cut on coronal 1 cm-thick sections, frozen in dry ice and
stored at −80 °C until use.
All sporadic PD cases had suffered from classical parkinsonism and
none of them had apparent cognitive impairment or dementia. Cases
analyzed here were tested for the G2019S LRRK2 mutation and were
found negative for this mutation.
A complete neuropathological examination was performed in all
cases using formalin-fixed tissue which was embedded in paraffin no
less than three weeks later basically as previously described [32,33].
Neuropathological characterization of PD was according to estab-
lished criteria [7], and PD cases corresponded to stage 4 of Braak and
Braak, implying involvement of selected nuclei of the medulla oblon-
gata, pons and midbrain, amygdala and nucleus basalis of Meynert. All
PD cases showed marked loss of neurons in the substantia nigra pars
compacta exceeding 60%, whereas moderate pathology occurred in the
caudate and putamen. In no case did Lewy pathology involve the
frontal cortex. Diagnostic determination of LBD was carried out
following consensus guidelines [9], and staging of AD changes was
performed following Braak and Braak criteria [10]. According to those
criteria, LBD cases were stages 4/5, and AD cases were stage 5. Control
subjects showed absence of neurological symptoms, metabolic and
vascular diseases, and the neuropathological study disclosed no
abnormalities including lack of PD- and AD-related pathology.
Postmortem slices (around 0.07 g) were resuspended in pure HNO3
(500 μl) and incubated at 65 °C for 2 h, and lysates were mixed and
sonicated twice during this incubations, followed by centrifugation at
3500 x g for 30 min at 4 °C. An aliquot was taken for quantification of
iron content and the remainder was frozen down. Samples were
subjected to AAS upon a 1:10 dilution in MilliQ H2O. Total iron content
was normalized to tissue wet weight. Three independent sections were
analyzed per brain region and patient to obtain an averaged value of
total iron content.
2.4. Atomic absorption spectroscopy
An AAnalyst 800 atomic absorption spectrometer (Perkin Elmer,
Norwalk, USA) equipped with a flame was used for iron determination.
Mono-elementary hollow cathode lamps (Perkin Elmer) for iron,
operating at the recommended currents, were employed as light source.
Certified reference solutions of iron for AAS (titrisol grade, Merck) were
used to generate standard curves, and dilutions prepared using reverse
osmosis type quality water produced by Milli-RO 12 plus Milli-Q
purification system (Millipore, Bedford, MA, USA). Standard curves
ranged from zero to 5 mg iron/l (linear equation through zero,
correlation coefficient 0.997), and the total iron concentrations deter-
mined from the standard curve were normalized to either total protein
concentration or wet tissue weight as indicated. Analytical method for
the determination of iron was previously validated. The validation
parameters for the analytical procedure included calibration curve
range, LOD/LOQ, precision (minimal, intermediate and reproducibil-
ity), and recovery percentage.
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2.5. Sample preparation and analysis by western blotting
Postmortem brain lysates were prepared from slices of individual
tissues, extracts were resolved by sodium dodecylsulfate-polyacryla-
mide gel electrophoresis followed by Western blotting as previously
described [33]. The following antibodies were employed: a mouse
monoclonal anti-LAMP2 (H4B4) (1:2000, Santa Cruz Biotechnology,
sc18822), a mouse monoclonal anti-LAMP1 (H4A3) (1:2000, Santa
Cruz Biotechnology, sc20011), a rabbit monoclonal anti-ACTIN (1:400,
Sigma-Aldrich, A2066/030M4844), a monoclonal anti-α-Tubulin
(clone DM1A, 1:10,000, Sigma-Aldrich T6199), a rabbit polyclonal
Anti-Phospho-AKT473 antibody (1:500, Cell Signaling, 9271), a rabbit
polyclonal Anti-AKT antibody (1:500, Cell Signaling, 9272), a rabbit
polyclonal Anti-Phospho-ERK antibody (1:500, Cell Signaling, 4370) or
a rabbit polyclonal anti-ERK antibody (1:500, Cell Signaling, 4695).
The final detection was performed as previously described [33].
2.6. Statistical analysis
Data are represented as mean ± SEM. Statistical comparisons were
made using analysis of variance (ANOVA), and a p value< 0.05 was
considered statistically significant.
3. Results
3.1. Effects of ferric ammonium citrate (FAC) on iron concentration in
cultured cells
Our previous studies have shown that treatment of cultured cells
with ferric ammonium citrate (FAC) causes an increase in oxidative
stress associated with endolysosomal alterations and impaired autop-
hagy which may be associated with disease pathomechanism(s) [28].
To corroborate that these effects were due to underlying increases in
total cellular iron content, we subjected HEK293T cells to increasing
concentrations of FAC for either 24 h or 48 h, and determined total iron
concentration by AAS (Fig. 1A,B) as previously validated (calibration
curve range: 0–5 mg L−1; LOD/LOQ: 0.16/0.54 mg L−1; precision
(minimal-intermediate-reproducibility) 1.03-2.57-4.46; % recovery
101). There was a dose- and time-dependent increase in iron content
which matched the previously determined dose- and time-dependent
increase in apoptosis, indicating that an increase in total iron was the
underlying cause for the observed changes in cell viability [28]. Since
cells with dopaminergic features such as PC12 cells have been found to
display increased apoptosis upon FAC treatment as compared to
HEK293T cells [28], we compared total iron concentrations in the
presence or absence of FAC treatment amongst the two distinct cell
types. PC12 cells were found to display increased cellular iron load as
compared to HEK293T cells (Fig. 1C), suggesting that the underlying
differences in cell viability are due to differences in intracellular iron
load in those two distinct cell lines, rather than due to differential iron
sensitivities.
3.2. Region-specific differences in total iron in mouse brain
Various protocols for tissue solubilization have been described,
including pure nitric acid either in the presence or absence of H2O2, or
lysis buffers containing detergents [34,29,31]. In addition, different
times and temperatures have been employed, ranging from 2 − 12 h
and 65 − 90 °C. A careful repetitive and side-by side analysis of the
different protocols was performed using cortical tissue from mice. Most
accurate and reproducible AAS results were obtained using pure nitric
acid for 2 h at 65 °C, which completely dissolved tissue sections, and
normalization of total iron content determined by AAS to tissue wet
weight rather than to estimations of total protein concentrations, and
this methodology was employed in all further studies.
We probed for region-specific and age-dependent alterations in total
iron content in mouse brain tissue. AAS analysis was performed on
distinct brain regions obtained from either an inbred (Fig. 2A) or an
outbred (Fig. 2B) mouse strain. Total iron content was found to be
higher in SN as compared to cortex or cerebellum in both strains, and
no differences were observed between the two genotypes (Fig. 2A,B).
Furthermore, no differences in iron content in the distinct brain regions
were observed between female and male samples, or between samples
from 2 month-old versus 9 month-old mice, respectively (Fig. 2).
Altogether, these data show increased iron content in rodent SN as
compared to other brain areas without genotype-specific, sex-specific or
age-specific alterations.
3.3. Region-specific differences in total iron content in human brain samples
from control and PD patients
To minimize variability, samples were carefully chosen according to
the following criteria: a) control and disease patients were age- and sex-
matched; b) samples were collected within a short postmortem interval,
and the pH of the cerebral spinal fluid was within a normal range; c)
patient samples were collected from one hemisphere, directly frozen
and kept at − 80 °C, whilst the other hemisphere was subjected to a
detailed neuropathological analysis; d) samples had comparable disease
stage; e) frozen sections were dissolved with pure nitric acid for 2 h at
65 °C in all cases; f) independent iron determinations were performed
Fig. 1. FAC causes a dose- and time-dependent increase in total iron levels in cultured cells, and a further increase in cultured cells possessing dopaminergic features. (A) HEK293T cells
were exposed to the indicated concentrations of FAC for 24 h, and iron content quantified by AAS. (B) HEK293T cells were exposed to the indicated concentrations of FAC for 48 h, and
iron content quantified by AAS. (C) HEK293T cells or dopaminergic PC12 cells were exposed to the indicated concentrations of FAC for 48 h, and iron content analyzed by AAS. Bars
represent mean ± SEM (n = 3; * p < 0.05; ** p < 0.01; *** p < 0.005).
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on 3 individual sections per region per patient; and g) iron concentra-
tion was normalized to wet weight of the frozen sections rather than to
total protein content (for further details see Materials and methods).
We first analyzed iron content in the cortex, cerebellum and caudate
from age- and sex-matched control versus PD patients. Iron content was
significantly higher in the caudate as compared to cortex and cerebel-
lum, but there were no differences observed between PD and control
samples (Fig. 3). Thus, at least in this sample set, there are no
discernible differences in iron content in the caudate nucleus, even
though LBs in that area are present during the PD disease stage
analyzed here.
3.4. Analysis of signalling cascades and endolysosomal alterations in
human brain samples from control and PD patients
As another means to determine a link between iron-related events
and cellular demise, we performed a biochemical analysis on patient
samples. Animal studies using distinct oxidative stress-induced PD
models have shown activation of select signalling cascades including
kinases of the MAPK superfamily such as Erk1/2 [35]. Furthermore, in
SN from PD patients a link was observed between aberrant kinase
activation and LB pathology in non-apoptotic cells, suggesting an early
role for some of those kinases in LB formation [32,36]. Similarly,
alterations in the phosphorylation status of Akt/PKB have been
reported in animal models as well as in the SN of PD patients
[37,38,39]. Akt/PKB is known to regulate mTORC1 activity which in
turn modulates autophagy, a process whereby cytoplasmic constituents
such as protein aggregates are engulfed within specialized double-
membrane vesicles (autophagosomes) and delivered to the lysosome for
degradation, and SN samples from PD patients display altered levels of
endolysosomal markers [40,41]. Therefore, we determined levels of
total and/or phosphorylated (activated) forms of Erk1/2 and Akt/PKB,
as well as total levels of endolysosomal markers (LAMP1, LAMP2) from
postmortem extracts of control and PD subjects (Fig. 4). Even though
affected by disease pathology, no significant changes in the levels of the
respective proteins were detectable in the caudate nucleus of PD versus
control patients (Fig. 4), in agreement with a detectable lack of total
iron content as measured by AAS.
3.5. Increase in total iron content in SN from LBD as compared to AD and
healthy control patients
LBD is clinically associated with memory/cognitive deficits as well
as a movement disorder phenotype. As sharing clinical features with
AD, it can be misdiagnosed in the early stages of the disease.
Neuropathologically, it is characterized by LB in the SN as well as
many other brain areas [8,9], and the common form of LBD also
presents with AD pathology. Thus, comparing iron content in the SN
from LBD versus AD samples allows for correlating altered iron
concentration with LB pathology and parkinsonian features in LBD
patients. SN samples from moderate (stage 4/5) LBD or moderate/
severe (stage 5) AD were compared to age- and sex-matched healthy
controls. AAS determination of total iron content revealed a significant
increase in SN from LBD, but not AD patients, as compared to controls
(Fig. 5). Thus, the presence of LB pathology and neurodegeneration in
the SN of LBD samples, absent from AD samples, correlates with an
increase in iron content in this brain area.
4. Discussion
Here, we have analyzed total iron content in cellular systems as well
as in mouse and human brain samples to determine region-specific
differences in total iron content in the context of several neurodegen-
erative disorders. Our results show regional differences in iron con-
centration in distinct rodent and human brain areas. Importantly, our
refined detection approach allowed us to determine significant in-
creases in total iron in the SN of LBD patients as compared to AD
patients or healthy controls. Our data indicate a positive correlation
between iron dyshomeostasis in the SN and neurodegeneration asso-
ciated with LBD, which may aid in establishing iron-based imaging
methods for clinical diagnoses.
Our data indicate that dopaminergic cells are more prone to iron-
induced cytotoxicity as compared to non-dopaminergic cells because
they display an increase in iron load, rather than an increase in inherent
susceptibility towards iron. Several factors may contribute to this
observation, including differences in iron uptake and/or export or
altered iron storage. Iron is stored in non-toxic form in ferritin, and is
also present in mitochondria and the endolysosomal system [5]. In
Fig. 2. Increase in iron content in the SN of mice as determined by AAS. (A) Cortex, cerebellum and SN iron content was determined by AAS from female or male, and 2-month or 9-month
old outbred CD1 animals as indicated. Bars represent mean ± SEM (n = 3; * p < 0.05). (B) Cortex, cerebellum and SN iron content was determined by AAS from female or male 9-
month old inbred C57BL/6 mice as indicated. Bars represent mean ± SEM (n = 4; * p < 0.05).
Fig. 3. Iron content in the cortex, cerebellum and caudate nucleus from healthy control
and age- and sex-matched PD patients. Iron content from the distinct brain areas was
determined by AAS. Bars represent mean ± SEM (n = 3; *** p < 0.005).
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dopaminergic neurons, large amounts of iron are additionally seques-
tered in neuromelanin granules [5], and oxidative stress has been
shown to increase tyrosine hydroxylase activity and thus neuromelanin
production in PC12 cells [42]. Thus, whilst further studies will be
required to elucidate the mechanism(s) underlying the differential iron
load capacities, the increase in iron concentration in cell lines with
dopaminergic as compared to non-dopaminergic features may be, at
least in part, due to the presence of neuromelanin.
Our study describes refined conditions to determine total iron
content by AAS from distinct rodent brain areas. This allowed us to
detect increased iron in the rodent SN as compared to other brain areas,
which has not been previously detected [31]. The region-specific
differences in iron levels in the mouse brain were not dependent on
genetic background (inbred versus outbred strains), and no sex-specific
differences were observed, indicating that total iron content in rodent
model systems is comparable amongst different genetic backgrounds
and sexes. Furthermore, no differences in iron content were observed
between two-month and nine-month old mice. In humans, total iron
concentrations in the SN are known to linearly increase with healthy
ageing [2], and an age-dependent increase in total iron in the SN of
mice has been previously reported [43]. However, this study compared
brain iron in animals aged 5-months versus 14-months old using
another methodology, and also reported age-dependent increases in
iron load in the cerebellum. Therefore, it currently remains unclear
whether animal models can faithfully recapitulate the region-specific
and age-specific increase in total iron content observed in human brain
during healthy ageing.
The total levels of iron determined in the cortex, cerebellum and
caudate nucleus from age- and sex-matched human control patients
were similar to a subset of previous reports [11,15,18,20], with caudate
nucleus displaying an almost three-fold increase in total iron content as
compared to cortex or cerebellum. Several postmortem and especially
MRI-based in vivo studies have reported an increase in iron content in
the caudate nucleus of PD patients, and this brain area is affected
during relatively early disease stage [6,7]. However, we did not observe
significant changes in total iron content between control and PD
patients in the caudate, with all PD patient samples from the same
disease stage. Similarly, even though we have previously been able to
detect alterations in the phosphorylation state of select proteins
implicated in PD pathogenesis in this brain area [33], no alterations
in the activation state and/or levels of a set of kinases known to be
activated upon oxidative stress, or in the levels of proteins implicated in
endolysosomal events were detected. Thus, the reported discrepancies
in total iron content in the caudate nucleus may have been due to the
different methodologies employed, and/or due to differences in disease
stage [2], with changes possibly only becoming evident in severe
disease cases.
In AD patients, iron has been shown to accumulate in the cortex and
hippocampus, but not the cerebellum [44,1]. In contrast, there are
virtually no reports on brain iron levels from LBD patients [3]. Apart
from sharing many clinical features with AD patients as related to
cognitive decline, LBD patients also display parkinsonian features,
which correlates with LBs in the SN as well as other brain areas upon
postmortem analysis. We determined iron levels in the SN from control,
Fig. 4. Analysis of activation status and total levels of several protein kinase pathways and endolysosomal proteins implicated in PD. Protein extracts from caudate nucleus were analyzed
by Western blotting for differences in the phosphorylation status and/or total protein levels between control and PD patient samples as indicated.
Fig. 5. Increase in total iron content in the SN from LBD patients as compared to AD
patients or healthy controls. Total iron content in the SN was determined by AAS from
control, LBD and AD patients as indicated. Bars represent mean ± SEM (n = 5; *
p < 0.05).
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AD and LBD cases. A significant increase in total iron content was
observed in age- and disease stage-matched SN samples from LBD cases
as compared to AD or control.
The lack of iron accumulation in the SN of AD patients is consistent
with the pathological profile of neurodegeneration in AD. Conversely,
an increase in total iron content in the SN of LBD patients is consistent
with the correlation between increased iron and movement disorder
phenotype in PD patients. Interestingly, an in vivo imaging study has
shown that iron accumulation in the SN may be a predictor of
parkinsonism during the course of AD [45]. In addition, quantitative
susceptibility mapping (QSM), a novel sensitive method for determin-
ing iron concent in vivo, has recently been shown to detect regionally
progressive iron accumulation in a manner dependent on disease
severity [13,46]. Whilst future studies will be required to corroborate
the present observations, our data suggest that iron imaging studies in
patients suffering from AD, AD with parkinsonism, PD or LBD may aid
in clinical diagnosis and/or serve as biomarker for disease progression.
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